Every 40 seconds, someone in the United States has a stroke. Every 3.5 minutes, someone dies from one. Despite decades of medical progress, stroke remains the fifth leading cause of death in America and the leading cause of long-term adult disability — and for the roughly 800,000 Americans who survive a first stroke each year, the fear of a second one looms large. That fear may soon have a better answer.
New clinical research is reshaping how physicians approach stroke prevention, particularly for survivors at high risk of recurrence. At the same time, millions of people still don't know the warning signs, and many who do hesitate too long before calling 911. This article covers what stroke is, what's changing in treatment, and what the latest science means for patients and families navigating this reality right now.
Understanding Strokes: What Actually Happens in the Brain
A stroke occurs when blood flow to part of the brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients. Brain cells begin dying within minutes. The two primary types have fundamentally different causes and treatments:
- Ischemic stroke — accounts for approximately 87% of all strokes. Caused by a clot blocking a blood vessel in or leading to the brain. These are further divided into thrombotic strokes (clots forming in the brain's arteries) and embolic strokes (clots that form elsewhere and travel to the brain).
- Hemorrhagic stroke — caused by a ruptured blood vessel that bleeds into or around the brain. Though less common, hemorrhagic strokes carry a higher mortality rate.
- Transient ischemic attack (TIA) — often called a "mini-stroke," a TIA causes temporary stroke-like symptoms that resolve within 24 hours. A TIA is not harmless: roughly 10–15% of people who have one will have a full stroke within 3 months, with the highest risk in the first 48 hours.
The speed of cell death is why physicians use the phrase "time is brain." An untreated ischemic stroke destroys approximately 1.9 million neurons per minute. A person experiencing a major stroke loses as many neurons in an hour as the brain normally loses in 3.6 years of aging.
Recognizing the Warning Signs: FAST and Beyond
The most widely used recognition tool is the FAST acronym:
- Face — Ask the person to smile. Does one side droop?
- Arm — Ask them to raise both arms. Does one drift downward?
- Speech — Ask them to repeat a simple phrase. Is it slurred or strange?
- Time — If any of these signs are present, call 911 immediately.
More recent clinical guidelines have expanded this to BE-FAST, adding:
- Balance — sudden loss of balance or coordination
- Eyes — sudden blurred or double vision, or loss of vision in one or both eyes
One of the most dangerous patterns in stroke outcomes is delayed care. Surveys consistently show that people wait — sometimes hours — hoping symptoms will pass. With ischemic stroke, the clot-busting drug tPA (tissue plasminogen activator) is effective only within a 3–4.5-hour window from symptom onset. Missing that window eliminates one of the most powerful tools available. Having a medical alert device can be particularly valuable for stroke-risk patients who live alone, where time lost to delayed discovery is a common and preventable tragedy.
The Repeat Stroke Problem: Why Second Strokes Are So Dangerous
Surviving a stroke dramatically increases your risk of having another one. In the first 90 days after a stroke, the risk of recurrence is 3–10%. Over five years, roughly one in four stroke survivors will have another stroke. Each recurrence carries a higher chance of severe disability or death because the brain has less reserve capacity to compensate.
For decades, the standard of care for secondary prevention has relied heavily on antiplatelet drugs like aspirin or clopidogrel, along with statins and blood pressure management. These reduce risk but don't eliminate it — and they come with their own trade-offs, including bleeding risk.
This is why a new drug class currently in late-stage trials is generating significant attention among neurologists and cardiologists.
Bayer's Experimental Blood Thinner: A Potential Breakthrough
In a significant development for stroke medicine, Bayer's experimental blood thinner has shown it can cut both the risk and severity of repeat strokes in clinical trial results. The drug, asundexian, is a Factor XIa inhibitor — a next-generation anticoagulant targeting a different coagulation pathway than existing blood thinners.
Traditional anticoagulants like warfarin and newer drugs like rivaroxaban or apixaban (NOACs) work by broadly inhibiting the clotting cascade. This is effective but increases systemic bleeding risk — a serious concern for brain injury patients. Factor XIa inhibitors are designed to interfere with clot formation in a more targeted way, preserving the hemostatic clotting needed to stop bleeding from wounds while reducing pathological clotting in blood vessels.
The OCEANIC-AF trial, one of the pivotal studies for asundexian, enrolled patients with atrial fibrillation — a major source of embolic strokes. Early Phase 2 results showed promising reductions in clot-related events without the magnitude of bleeding seen with conventional anticoagulants. The latest data extends these findings to stroke recurrence specifically, suggesting the drug could become a meaningful upgrade over current second-line therapy.
For context: atrial fibrillation (AFib) is responsible for approximately 15–20% of all ischemic strokes, and the annual stroke risk in untreated AFib patients is 5% — five times higher than the general population. A safer, more effective anticoagulant for this population would address one of the highest-burden stroke risk cohorts in medicine.
Risk Factors: What You Can and Can't Control
Stroke risk is shaped by a combination of fixed and modifiable factors. Understanding both gives a clearer picture of where prevention efforts have leverage.
Non-Modifiable Risk Factors
- Age — Stroke risk doubles each decade after age 55. Two-thirds of strokes occur in people over 65.
- Sex — Men have a higher stroke rate overall, but women have higher lifetime risk due to longer lifespan, and stroke outcomes tend to be worse in women.
- Race and ethnicity — Black Americans have nearly twice the stroke risk of white Americans, driven by higher rates of hypertension, diabetes, and sickle cell disease.
- Family history and genetics — First-degree relatives of stroke patients face elevated risk; certain genetic conditions like CADASIL directly cause stroke.
Modifiable Risk Factors
- High blood pressure — The single most important modifiable risk factor. Hypertension accounts for approximately 54% of strokes worldwide. Target: below 130/80 mmHg. Regular monitoring with a home blood pressure monitor is one of the most cost-effective tools for ongoing stroke prevention.
- Atrial fibrillation — Treated with anticoagulation; the landscape here is improving with drugs like asundexian.
- Diabetes — More than doubles stroke risk.
- Smoking — Doubles stroke risk; cessation begins reducing risk almost immediately.
- High cholesterol — Contributes to atherosclerosis and arterial plaque.
- Physical inactivity, obesity, and diet — Compound multiple risk pathways simultaneously.
Treatment: From the ER to Rehabilitation
Acute ischemic stroke treatment has advanced considerably since the late 1990s introduction of tPA. Today's toolkit includes:
- IV tPA (alteplase or tenecteplase) — Clot-dissolving drug administered within 4.5 hours; tenecteplase has largely replaced alteplase at leading stroke centers due to ease of administration and comparable or superior outcomes.
- Mechanical thrombectomy — A catheter-based procedure that physically removes large clots from brain arteries. Effective up to 24 hours from onset in selected patients. Thrombectomy has been one of the most transformative advances in acute stroke care, dramatically improving outcomes for large vessel occlusions.
- Blood pressure management — Critical in both types; overly aggressive lowering can worsen ischemic stroke outcomes.
Post-acute care is where outcomes often diverge most. Stroke rehabilitation — physical therapy, occupational therapy, speech-language pathology — can meaningfully restore function when started early and sustained. Stroke rehabilitation equipment for home use, including grip strengtheners and therapy putty, is increasingly used to supplement formal PT between sessions.
What This Means: Analysis of the Emerging Treatment Landscape
The significance of drugs like asundexian isn't just pharmacological — it's logistical. One of the persistent challenges in anticoagulation therapy is adherence. Warfarin requires regular INR monitoring and dietary management. Many patients discontinue even NOACs due to perceived bleeding risk or cost. A drug that reduces repeat strokes with a more favorable safety profile could translate directly into higher real-world adherence — which is where most treatment benefit is actually captured or lost.
The broader trend in stroke medicine is toward personalization. Genomic biomarkers are beginning to identify patients with cryptogenic stroke (no identified cause) who have underlying coagulopathies previously undetected. Wearable ECG patches and implantable loop recorders are catching paroxysmal AFib that standard monitoring misses. Artificial intelligence is being integrated into brain imaging to identify salvageable tissue faster and reduce time to thrombectomy.
The challenge is that these advances are uneven in distribution. Comprehensive stroke centers with 24/7 thrombectomy capability are concentrated in urban academic medical centers. Rural and underserved communities — which already bear a disproportionate stroke burden — often lack both rapid transport and the downstream care infrastructure for rehabilitation. Asundexian, if approved, would be effective only if prescribed; and for patients without specialist access, the gap between what's possible and what's delivered remains wide.
The most actionable takeaway from current stroke research is the continued primacy of prevention over treatment. Blood pressure control, AFib detection and management, and smoking cessation remain the highest-leverage interventions available — and they're available now, not pending FDA approval.
Frequently Asked Questions About Strokes
What is the difference between a stroke and a TIA?
A TIA (transient ischemic attack) causes the same symptoms as a stroke — facial drooping, arm weakness, speech difficulty — but these symptoms resolve completely within 24 hours, typically within an hour. The distinction matters because TIAs indicate high stroke risk and require urgent evaluation, not a "wait and see" approach. Anyone who experiences TIA symptoms should go to an emergency room immediately, even if they feel fine by the time they arrive.
Can young people have strokes?
Yes, and the rate is rising. Approximately 10–15% of strokes occur in people under 45. Risk factors in younger adults include illicit drug use, patent foramen ovale (a structural heart defect), migraine with aura, hormonal contraception combined with smoking, and hypercoagulable conditions. Young survivors often face a different set of challenges: they're more likely to be working, raising families, and have longer post-stroke life spans — making rehabilitation and secondary prevention especially consequential.
How effective are blood thinners in preventing stroke?
For AFib-related stroke, anticoagulants reduce risk by approximately 60–70% compared to no treatment. Antiplatelet agents like aspirin are less effective for AFib but remain important in other stroke subtypes. The key tradeoff is bleeding risk — intracranial hemorrhage from anticoagulation, while rare, is often devastating. This is precisely why Factor XIa inhibitors like asundexian are compelling: early data suggests similar stroke prevention with reduced bleeding risk, which would significantly improve the risk-benefit equation, especially in older patients.
What should I do immediately if I think someone is having a stroke?
Call 911 immediately — do not drive them yourself unless there is no other option. Note the time when symptoms first appeared; this determines whether tPA is an option. Do not give them food, water, or medication. Keep them calm and still. If they become unresponsive and stop breathing, begin CPR. The emergency dispatcher can guide you through steps while help is on the way.
What long-term disabilities can result from a stroke?
Stroke is the leading cause of long-term disability in adults. Depending on location and severity, survivors may experience hemiplegia (paralysis on one side), aphasia (language and speech impairment), cognitive deficits including vascular dementia, depression and emotional dysregulation, dysphagia (swallowing difficulty), vision loss, and chronic fatigue. Recovery trajectory varies enormously — early intensive rehabilitation is the strongest predictor of functional improvement, and neuroplasticity means meaningful recovery can continue for months to years post-stroke with sustained effort.
Conclusion: Where Stroke Medicine Is Heading
Stroke is not a single disease but a spectrum of vascular events with different causes, severities, and optimal treatments. The good news is that the field is moving faster than at any point in its history — from the mechanical thrombectomy revolution of the last decade to the promising new anticoagulants entering trials today, the tools available to prevent and treat stroke are genuinely improving.
Bayer's work on asundexian represents exactly the kind of incremental but meaningful progress that accumulates into substantially better outcomes over time. If it clears FDA approval, it won't eliminate stroke — but it could keep hundreds of thousands of high-risk patients from experiencing a second, often more devastating event.
For individuals, the calculus hasn't changed: know the warning signs, manage blood pressure aggressively, don't ignore a TIA, and get to a stroke center fast when symptoms appear. Time is brain. The science is getting better at buying more of it — but only if patients and bystanders act quickly enough to put that science to work.
